Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 genotypes were assessed in 279 patients with alcoholic- and 253 patients with HCV-related cirrhosis.
|
23069476 |
2013 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 genotypes were also associated with higher risk of developing liver fibrosis and cirrhosis in dominant (aOR: 1.98, P=2.20*10-5; aOR: 1.67, P=0.008, respectively) and recessive (aOR: 3.94, P=5.16*10-5; aOR: 3.02, P=0.003, respectively) models.
|
28338112 |
2017 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 I148M was associated with a stepwise increase in liver fat content of up to 28% in MM vs. II-homozygotes (P-trend = 0.0001) and with ORs of 2.03 (1.52-2.70) for NAFLD (P = 3×10-7), 3.28 (2.37-4.54) for cirrhosis (P = 4×10-12), and 0.95 (0.86-1.04) for IHD (P = 0.46).
|
29228164 |
2018 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
|
31527889 |
2019 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 270 HBV-infected patients, concurrent fatty liver was found in 107 patients (39.6%) and was associated with metabolic risks, cirrhosis (P = 0.016) and PNPLA3 rs738409 CG/GG genotype (P = 0.002).
|
27547913 |
2017 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among nine studies, with 2,937 patients, PNPLA3 was associated with increased risk of HCC in patients with cirrhosis (OR 1.40, 95% CI 1.12-1.75).
|
24445574 |
2014 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriage of rs738409:G in PNPLA3 is associated with an increased risk of developing alcohol-related cirrhosis and has a significant negative effect on survival.
|
28161471 |
2017 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriage of HSD17B13 rs72613567:TA attenuated the risk for developing cirrhosis associated with PNPLA3 rs738409:G in both men and women but the protective effect against the subsequent development of HCC was only observed in men (p=1.72×10-4; ORallelic, 0.75; 95% CI, 0.64-0.87).
|
31630428 |
2019 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease.
|
21334404 |
2011 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis.
|
29895985 |
2018 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Frequency of the PNPLA3 minor (G) allele was increased in patients with NASH-cirrhosis compared with non-cirrhotic NAFLD and controls (allele frequency: 0.598 versus 0.367 versus 0.2, respectively, p < 0.001), and different between the latter two groups (p < 0.001).
|
27150500 |
2016 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n=1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis.
|
24978903 |
2014 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
|
29535416 |
2018 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygous carriers of the PNPLA3 variant are prone to develop cirrhosis in the absence of other risk factors such as alcohol or viral hepatitis.
|
24222094 |
2013 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, 1 patient with NAFLD-related cirrhosis was compound heterozygous for rare damaging mutations in PNPLA3.
|
24081230 |
2013 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In ALD&NAFLD patients, the PNPLA3 148M allele was associated with younger age, shorter history of cirrhosis, less advanced (Child A) cirrhosis at HCC diagnosis, and lower HCC differentiation grade (p<0.05).
|
24155878 |
2013 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, PNPLA3 148M allele carriers showed an increased incidence of cirrhosis (P-value < 0.001).
|
24102786 |
2014 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No significant differences in the genotype distribution of PNPLA3 (P = 0.90) or TM6SF2 (P = 0.72) were observed between patients with cirrhosis and patients without cirrhosis.
|
30161167 |
2018 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of note, the PNPLA3 risk variant advances fibrosis in the total cohort as well as in the subgroups of patients with viral hepatitis and non-viral liver diseases and contributes 16% of the total cirrhosis risk.
|
21168459 |
2011 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, these results suggest that rs738409 exerts a marked influence on hepatocarcinogenesis in patients with cirrhosis of European descent and provide a strong argument for performing further mechanistic studies to better understand the role of PNPLA3 in HCC development.
|
24114809 |
2014 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Personalized strategies employing the genetic risk conferred by ATG16L1 and PNPLA3 may be used for risk-based surveillance in cirrhosis.
|
31484215 |
2019 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prdevious meta-analyses assess whether or not patatin-like phospholipase domain containing 3 (PNPLA3) (rs738409 C > G) was associated with increased risk of hepatocellular carcinoma (HCC) in Caucasians patients with hepatitis C virus (HCV)-related cirrhosis, these meta-analyses did not provide firm conclusions.
|
29089161 |
2018 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous studies of the PNPLA3 I148M sequence variant in HCV infected individuals have reported an association between this variant and prevalence of steatosis, fibrosis, and cirrhosis.
|
22978414 |
2012 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Second, although the strongest genetic risk alleles for NAFLD (ie, the 148Met allele in PNPLA3 and the 167Lys allele in TM6SF2) are associated with increased liver fat content and progression to NASH and cirrhosis, these alleles are also unexpectedly associated with an apparent protection from cardiovascular disease.
|
30174213 |
2019 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.
|
25504078 |
2014 |